Deutsche Märkte schließen in 5 Stunden 42 Minuten

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
58,32-2,77 (-4,53%)
Börsenschluss: 04:00PM EDT
55,41 -2,91 (-4,99%)
Nachbörse: 05:07PM EDT

Apellis Pharmaceuticals, Inc.

100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700
https://www.apellis.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter476

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Cedric Francois M.D., Ph.D.Co-Founder, Pres, CEO & Director969,54k3,65M1972
Dr. Pascal Deschatelets Ph.D.Co-Founder & Chief Scientific Officer609,85k1,44M1970
Dr. Federico Grossi M.D., Ph.D.Co-Founder & Chief Medical Officer578,01k1,79M1974
Mr. Alec Machiels J.D., MBACo-Founder & Director72,5kN/A1973
Mr. Timothy E. SullivanCFO & Treasurer630,17k1,96M1971
Mr. Adam J. TownsendChief Commercial Officer602,69kN/A1977
Ms. Nur NicholsonChief Technical Operations OfficerN/AN/AN/A
Mr. James G. Chopas CPAVP, Corp. Controller & Chief Accounting OfficerN/AN/A1966
Ms. Meredith KayaSr. VP, Investor Relations & Strategic Fin.N/AN/AN/A
Mr. David O. WatsonGen. CounselN/AN/A1973
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Corporate Governance

Apellis Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. September 2022, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 8, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.